Philip Bonomi to Carcinoma, Bronchogenic
This is a "connection" page, showing publications Philip Bonomi has written about Carcinoma, Bronchogenic.
Connection Strength
0.319
-
Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):331-4.
Score: 0.080
-
Phase II trial of mitomycin, vindesine, and hexamethylmelamine in metastatic non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1986 Dec; 70(12):1447-8.
Score: 0.074
-
Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma. Semin Oncol. 1986 Sep; 13(3 Suppl 3):115-20.
Score: 0.073
-
Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide, methotrexate, and etoposide. Cancer Treat Rep. 1985 Sep; 69(9):1007-9.
Score: 0.068
-
Continuous infusion of etoposide, bolus administration of cisplatin, and simultaneous radiation therapy in previously treated patients with small cell bronchogenic carcinoma. NCI Monogr. 1988; (6):323-5.
Score: 0.020
-
Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy. Anticancer Res. 1981; 1(6):335-40.
Score: 0.003